Dexcom Inc. is experiencing a notable uptick in its stock price following significant advancements in diabetes care.
Dexcom Inc. (NASDAQ:DXCM) is rising today, up 3.55% to close at CA$86.43, driven by the recent publication of groundbreaking research supporting the use of continuous glucose monitoring (CGM) technology in Type 2 diabetes care.
Advertisement
DexCom Inc
DXCM.US
DXCM.US
DexCom Inc
WealthAwesomeMarket cap
$31.50B
P/E
33.1x
52W high
$92.59
52W low
$54.11
1W change
-0.98%
Beta
1.48
Analyst Price Targets
Based on 29 analysts covering DXCM · as of Oct 14, 2026
Wall Street analysts forecast DXCM stock price to rise 15.6% over the next 12 months.
Consensus
Strong Buy4.66 / 5.00
Avg. Target
C$96.46
+15.6% Upside
Previously C$96.23 on Oct 12, 2026
Current Price
C$83.47
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DXCM's historical volatility
30-Day Vol
24.9%
Annualized
90-Day Vol
38.4%
Annualized
Trend (90d)
+46.3%
Annualized drift
90d Mean
C$98.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$88.20 | C$80.94 – C$96.12 |
| 60 trading days | C$93.21 | C$82.54 – C$105.25 |
| 90 trading days | C$98.49 | C$84.87 – C$114.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The positive momentum in Dexcom's stock reflects growing confidence in its CGM technology and its potential to transform diabetes management, particularly for non-insulin-dependent patients.
Dexcom's stock up 3.55% after landmark study publication.
The CONNECT study demonstrated a significant 1.6% reduction in A1C levels among participants using the Dexcom G7, enhancing its credibility in the diabetes management space.
Bull case
The CONNECT study published in The New England Journal of Medicine provides strong evidence that Dexcom's G7 system works well. This could help the company reach more customers and boost sales.
Bear case
Even with this positive news, Dexcom faces tough competition in the CGM market, which might affect its growth and market share over time.
Advertisement
Breakthrough Research Boosts Dexcom's Credibility
The recent publication of the CONNECT study in The New England Journal of Medicine marks a significant milestone for Dexcom. The study showed that participants using the Dexcom G7 experienced an average A1C reduction of 1.6%, a notable improvement compared to routine care. This evidence not only validates Dexcom's technology but also positions it as a leader in diabetes management, especially for Type 2 diabetes patients not on insulin.
Market Response and Future Growth Potential
Investors are responding positively to the news, as reflected in the stock's 3.55% increase. The growing recognition of CGM technology's benefits could lead to increased adoption rates among healthcare providers. Dexcom's market capitalization now stands at approximately $31.5 billion, and with projections of a 22.6% growth rate over the next five years, the company is well-positioned for continued success in the expanding mHealth solutions market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
